Simcere Signs $170 Million Deal for Myelopreservation Therapy

Nanjing Simcere Pharma in-licensed Greater China rights to trilaciclib from North Carolina's GI Therapeutics in a $170 million agreement. Trilaciclib is a proposed myelopreservation therapy intended to improve chemotherapy treatment. Simcere will make a $14 million upfront payment and add up to $154 million in milestone payments, plus royalties. Trilaciclib has been granted US Breakthrough Therapy Designation following three double-blind trials in which it was administered before chemotherapy to patients with small cell lung cancer. More details.... Stock Symbol: (NSDQ: GTHX) Share this with colleagues: // //